{"id":169156,"date":"2025-07-16T10:03:06","date_gmt":"2025-07-16T14:03:06","guid":{"rendered":"https:\/\/44.250.171.167\/?p=169156"},"modified":"2025-07-16T10:03:06","modified_gmt":"2025-07-16T14:03:06","slug":"glenmark-pharmaceuticals-ltd-q4fy25-6-rise-in-revenue","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/glenmark-pharmaceuticals-ltd-q4fy25-6-rise-in-revenue\/","title":{"rendered":"Glenmark Pharmaceuticals Ltd Q4FY25; 6% rise in Revenue"},"content":{"rendered":"<p>Glenmark Pharmaceuticals Ltd is a global research-led pharmaceutical company with presence across generics, Specialty and OTC business with operations in over 80 countries.<\/p>\n<p>Financial Results:<\/p>\n<p>Glenmark Pharmaceuticals Ltd reported Revenues for Q4FY25 of \u20b93,256.20 Crores up from \u20b93,062.96 Crore year on year, a rise of 6.31%.<\/p>\n<p>Total Expenses for Q4FY25 of \u20b92,887.10 Crores up from \u20b92,858.51 Crores year on year, a rise of 1.0%.<\/p>\n<p>Consolidated Net Profit of \u20b94.38 Crores from -\u20b91,214.27 Crores in the same quarter of the previous year.<\/p>\n<p>The Earnings per Share is \u20b90.16, from -\u20b943.17 in the same quarter of the previous year.<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"aligncenter size-full wp-image-169157\" src=\"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/Y.png\" alt=\"\" width=\"1489\" height=\"1817\" srcset=\"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/Y.png 1489w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/Y-246x300.png 246w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/Y-839x1024.png 839w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/Y-768x937.png 768w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/Y-1259x1536.png 1259w\" sizes=\"auto, (max-width: 1489px) 100vw, 1489px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Glenmark Pharmaceuticals Ltd is a global research-led pharmaceutical company with presence across generics, Specialty and OTC business with operations in over 80 countries. Financial Results: Glenmark Pharmaceuticals Ltd reported Revenues for Q4FY25 of \u20b93,256.20 Crores up from \u20b93,062.96 Crore year on year, a rise of 6.31%. Total Expenses for Q4FY25 of \u20b92,887.10 Crores up from [&hellip;]<\/p>\n","protected":false},"author":1932,"featured_media":169157,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[105,392],"tags":[1115],"class_list":["post-169156","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-infographics","category-earnings","tag-pharmaceuticals"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/Y.png","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":169169,"url":"https:\/\/alphastreet.com\/india\/glenmark-pharmaceuticals-ltd-q4fy25-6-rise-in-revenue-2\/","url_meta":{"origin":169156,"position":0},"title":"Glenmark Pharmaceuticals Ltd Q4FY25; 6% rise in Revenue","author":"Divyansh_Kasana","date":"July 17, 2025","format":false,"excerpt":"Glenmark Pharmaceuticals Ltd is a global research-led pharmaceutical company with presence across generics, Specialty and OTC business with operations in over 80 countries. Financial Results: Glenmark Pharmaceuticals Ltd reported Revenues for Q4FY25 of \u20b93,256.20 Crores up from \u20b93,062.96 Crore year on year, a rise of 6.31%. Total Expenses for Q4FY25\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/U-11.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/U-11.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/U-11.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/U-11.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/U-11.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/U-11.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":168660,"url":"https:\/\/alphastreet.com\/india\/alivus-life-sciences-ltd-q4fy25-12-rise-in-revenue\/","url_meta":{"origin":169156,"position":1},"title":"Alivus Life Sciences Ltd Q4FY25; 12% rise in Revenue","author":"Divyansh_Kasana","date":"June 5, 2025","format":false,"excerpt":"Glenmark Life Sciences, a subsidiary of Nirma Limited, a diversified conglomerate with interest in consumer products, cement, chemicals and pharmaceuticals. It is a leading developer and manufacturer of select, high-value, non-commoditized, active pharmaceutical ingredients (APIs) in chronic therapeutic areas. The company further operates in Contract Development and manufacturing operations to\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/L-3.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/L-3.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/L-3.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/L-3.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/L-3.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/L-3.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":166692,"url":"https:\/\/alphastreet.com\/india\/glenmark-pharmaceuticals-ltd-q3fy25-16-fall-in-profits\/","url_meta":{"origin":169156,"position":2},"title":"Glenmark Pharmaceuticals Ltd Q3FY25; 16% fall in Profits","author":"Divyansh_Kasana","date":"February 5, 2025","format":false,"excerpt":"Glenmark Pharmaceuticals Ltd is a global research-led pharmaceutical company with presence across generics, Specialty and OTC business with operations in over 80 countries. Financial Results: Glenmark Pharmaceuticals Ltd reported Revenues for Q3FY25 of \u20b91,926.00 Crores up from \u20b92,507.00 Crore year on year, a rise of 5.77%. Total Expenses for Q3FY25\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/02\/O-2.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/02\/O-2.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/02\/O-2.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/02\/O-2.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/02\/O-2.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/02\/O-2.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":161939,"url":"https:\/\/alphastreet.com\/india\/glenmark-pharmaceuticals-ltd-q4fy24-2-rise-in-revenue\/","url_meta":{"origin":169156,"position":3},"title":"Glenmark Pharmaceuticals Ltd Q4FY24; 2% rise in Revenue","author":"Divyansh_Kasana","date":"June 6, 2024","format":false,"excerpt":"Glenmark Pharmaceuticals Ltd is a global research-led pharmaceutical company with presence across generics, Specialty and OTC business with operations in over 80 countries. Financial Results: Glenmark Pharmaceuticals Ltd reported Revenues for Q4FY24 of \u20b93,063.00 Crores up from \u20b93,001.00 Crore year on year, a rise of 2.07%. Total Expenses for Q4FY24\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/06\/image-59.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/06\/image-59.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/06\/image-59.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/06\/image-59.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/06\/image-59.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/06\/image-59.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":157442,"url":"https:\/\/alphastreet.com\/india\/glenmark-pharmaceuticals-ltd-q2fy24-6-rise-in-revenue\/","url_meta":{"origin":169156,"position":4},"title":"Glenmark Pharmaceuticals Ltd Q2FY24; 6% rise in Revenue","author":"Divyansh_Kasana","date":"December 19, 2023","format":false,"excerpt":"Glenmark Pharmaceuticals Ltd is a global research-led pharmaceutical company with presence across generics, Specialty and OTC business with operations in over 80 countries. Financial Results: Glenmark Pharmaceuticals Ltd reported Revenues for Q2FY24 of \u20b93,207.00 Crores up from \u20b93,018.00 Crore year on year, a rise of 6.26%. Total Expenses for Q2FY24\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/12\/image-137.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/12\/image-137.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/12\/image-137.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/12\/image-137.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/12\/image-137.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/12\/image-137.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":153153,"url":"https:\/\/alphastreet.com\/india\/glenmark-pharmaceuticals-ltd-q1fy24-18-fall-in-profits\/","url_meta":{"origin":169156,"position":5},"title":"Glenmark Pharmaceuticals Ltd Q1FY24; 18% fall in Profits","author":"Hardik Bhandare","date":"August 14, 2023","format":false,"excerpt":"Glenmark Pharmaceuticals Ltd is a global research-led pharmaceutical company with presence across generics, Specialty and OTC business with operations in over 80 countries. Financial Results: Glenmark Pharmaceuticals Ltd reported Revenues for Q1FY24 of \u20b93,402.00 Crores up from \u20b92,777.00 Crore year on year, a rise of 22.51%. Total Expenses for Q1FY24\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/08\/image-823.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/08\/image-823.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/08\/image-823.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/08\/image-823.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/08\/image-823.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/08\/image-823.png?resize=1400%2C800&ssl=1 4x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/169156","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/1932"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=169156"}],"version-history":[{"count":0,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/169156\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media\/169157"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=169156"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=169156"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=169156"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}